Methods of treating TSLP-related inflammatory disorders
The present disclosure provides compositions and methods relating to antigen binding proteins which bind to human thymic stromal lymphopoietin (TSLP), including antibodies. In particular embodiments, the disclosure provides fully human, humanized and chimeric anti-TSLP antibodies and derivatives of such antibodies. The disclosure further provides nucleic acids encoding such antibodies and antibody fragments and derivatives, and methods of making and using such antibodies including methods of treating and preventing TSLP-related inflammatory and fibrotic disorders.
1. A method of treating a TSLP-related inflammatory condition in a subject in need of such treatment comprising administering a therapeutically effective amount of a composition comprising an isolated TSLP antagonist antigen binding protein that specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein said TSLP antagonist antigen binding protein comprises:
a. a light chain variable domain comprising:
i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:13;
ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:60; and
iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:105; and
b. a heavy chain variable domain comprising:
i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:145;
ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:173, and
iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:212.
2. The method of claim 1 , wherein said TSLP antagonist antigen binding protein comprises either:
a. a light chain variable domain sequence selected from the group consisting of:
i. a sequence of amino acids at least 80% identical to SEQ ID NO:363;
ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:362; and
iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:362;
b. a heavy chain variable domain selected from the group consisting of:
i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:361;
ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:360; and
iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:360; or
c. a light chain variable domain of (a) and a heavy chain variable domain of (b).
3. The method of claim 2 , wherein said TSLP antagonist antigen binding protein comprises either:
a. a light chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:363;
b. a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:361; or
c. the light chain variable domain of (a) and the heavy chain variable domain of (b).
4. The method of claim 3 , wherein said TSLP antagonist antigen binding protein comprises the light chain variable domain of (a) and the heavy chain variable domain of (b).
5. The method of claim 1 , wherein said TSLP antagonist antigen binding protein binds to TSLP with substantially the same Kd as an antibody comprising a) a light chain comprising a light chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:363 and a lambda light chain constant domain comprising the amino acid sequence as set forth in SEQ ID NO:369; and b) a heavy chain comprising a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:361 and an IgG2 heavy constant domain comprising the amino acid sequence as set forth in SEQ ID NO:365.
6. The method of claim 1 , wherein said TSLP antagonist antigen binding protein inhibits TSLP activity to block osteoprotegerin (OPG) production from primary human dendritic cells with the same IC50 as an antibody comprising a) a light chain comprising a light chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:363 and a lambda light chain constant comprising the amino acid sequence as set forth in SEQ ID NO:369; and b) a heavy chain comprising a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:361 and an IgG2 heavy constant domain comprising the amino acid sequence as set forth in SEQ ID NO:365.
7. The method of claim 1 , wherein said TSLP antagonist antigen binding protein is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an IgD antibody, an IgE antibody, an IgM antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.
8. The method of claim 1 , wherein said TSLP antagonist antigen binding protein is a human antibody.
9. The method of claim 1 , wherein said TSLP antagonist antigen binding protein is a monoclonal antibody comprising one or more light chains and one or more heavy chains.
10. The method of claim 9 , wherein said TSLP antagonist antigen binding protein comprises a) a light chain comprising a light chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:363 and a lambda light chain constant domain comprising the amino acid sequence as set forth in SEQ ID NO:369; and b) a heavy chain comprising a heavy chain variable domain comprising the amino acid sequence as set forth in SEQ ID NO:361 and an IgG2 heavy constant domain comprising the amino acid sequence as set forth in SEQ ID NO:365.
11. The method of any of claims 1 - 10 , wherein the TSLP-related inflammatory condition is an allergic inflammatory disorder.
12. The method of claim 11 , wherein the allergic inflammatory disorder is a pulmonary inflammatory disease.
13. The method of claim 12 , wherein the pulmonary inflammatory disease is allergic asthma.
14. The method of any of claims 1 - 10 , wherein the TSLP-related inflammatory condition is asthma.